Table 3.
Univariate and multivariate analyses of breast cancer‐specific survival in 154 breast cancer patients examined
| Variable | Univariate | Multivariate | |
|---|---|---|---|
| P‐value | P‐value | Relative risk (95% CI) | |
| Ki‐67 LI | |||
| (0–60) | <0.0001 | 0.27 | |
| Chemotherapy(+NAC) | |||
| (+/−) | 0.0017 | 0.46 | |
| Histological grade | |||
| (1,2/3) | 0.0021 | 0.41 | |
| PR status | |||
| (positive/negative) | 0.0037 | 0.016 | 0.1 (0.002–0.6) |
| pT | |||
| (pT1/pT2‐4) | 0.011 | 0.34 | |
| Adjuvant endocrine therapy | |||
| (+/−) | 0.012 | 0.47 | |
| Estrogen receptor (ER) status | |||
| (positive/negative) | 0.020 | 0.65 | |
| Lymph node metastasis | |||
| (positive/negative) | 0.023 | 0.36 | |
| TACC2 status | |||
| (+/−) | 0.039 | 0.040 | 7.1 (1.1–146.6) |
| HER2 status | |||
| (positive/negative) | 0.75 | ||
Statistical analysis was evaluated by a proportional hazard model (Cox). Data considered significant (P < 0.05) in the univariate analyses were described as boldface, and these were examined in the multivariate analyses.